An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics

Authors:

Abstract
Treating infection by Gram-negative bacteria is increasingly challenging as resistance to existing antibiotics spreads. Constrained peptides, selected for high target specificity and affinity via library display technologies, are an emerging therapeutic modality in many disease areas and may be a fertile source of new antibiotics. Currently, the utility of constrained peptides and other large molecules as antibiotics is limited by the outer membrane (OM) barrier of Gram-negative bacteria. However, adding certain moieties to large molecules can confer the ability to cross the OM – these moieties function as intramolecular trans-OM “vectors”. Here, we present a method to systematically assess the carrying capacity of candidate trans-OM vectors using a real-time luminescence assay (“SLALOM”), reporting on periplasmic entry. We demonstrate the usefulness of our tools by constructing a 3800 Da chimeric compound comprised of a constrained bicyclic peptide (Bicycle®), with a periplasmic target, linked to an intramolecular peptide vector, the resulting chimera is a broad-spectrum inhibitor of pathogenic Gram-negative bacterial growth.

This publication has 26 references indexed in Scilit: